R&D
Therapeutics
Microbiome Therapeutics Pipeline - Oncology
Pipeline
Indication
Discovery
Preclinical
Clinical Development
Phase1
Phase2
Phase3
LABTHERA-002
Adjunctive Therapy with Cytotoxic Chemotherapy
Cytotoxic chemotherapies remain a cornerstone of cancer treatment and continue to be widely used in many indications where targeted therapies or immunotherapies offer limited benefit.
However, their non-selective toxicity often results in systemic side effects and treatment resistance, limiting their overall therapeutic potential.
However, their non-selective toxicity often results in systemic side effects and treatment resistance, limiting their overall therapeutic potential.
Growing evidence highlights the critical role of the gut microbiome in modulating both the efficacy and tolerability of cytotoxic chemotherapies.
Therapeutic approaches that restore and maintain microbiome balance represent a promising strategy to improve treatment outcomes.
Therapeutic approaches that restore and maintain microbiome balance represent a promising strategy to improve treatment outcomes.
LABTHERA-002 is being developed as a microbiome-based combination therapy designed to enhance the efficacy of cytotoxic chemotherapies through gut microbiome–mediated immune activation, while mitigating treatment-associated side effects such as cachexia and diarrhea.
LABTHERA-002 is currently preparing for a Phase 2a clinical study.